Skip to main content
. 2018 Jun 25;78(6):567–584. doi: 10.1055/a-0611-5549
Consensus-based Statement 6.S43
Expert consensus Strength of consensus +++
The risk of ovarian insufficiency following the administration of tyrosine kinase inhibitors (TKI) is unclear, with TKI reported to have a teratogenic potential.